Wednesday, April 30, 2025
3:00PM – 4:00PM ET
Please note this TeleECHO program is 3:00PM Eastern, 2:00PM Central, 1:00PM Mountain and 12:00PM Pacific.
PRESENTING FACULTY
 |
Mehdi Hamadani, MD Chief of Hematologic Malignancies Endowed Professor and Associate Director of Clinical Research Medical College of Wisconsin Milwaukee, WI |
PROGRAM OVERVIEW
This interactive educational activity aims to enhance the ability of hematologists/oncologists and the broader multidisciplinary oncology team with the latest insights into the evolving treatment landscape of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Expert-led discussion will explore the clinical significance of key biomarkers in guiding treatment decisions, the most recent safety and efficacy data on available therapies, and patient-specific factors influencing treatment choices. Additionally, the program will highlight strategies for recognizing and managing potential adverse events associated with current treatment options. Attendees will gain actionable knowledge to optimize care for patients with R/R DLBCL.
TARGET AUDIENCE
The proposed educational activities are specifically designed to meet the educational needs of academic and community medical hematologists/oncologists, as well as members of the multidisciplinary oncology team, such as oncology NPs/PAs, and oncology pharmacists.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Evaluate the role of specific biomarkers to inform clinical decisions in R/R DLBCL
- Summarize the efficacy and safety of specific therapies in R/R DLBCL and patient-specific factors informing choice of therapy in the setting of resistance to prior therapy
- Describe potential adverse events associated with available therapies for the management of R/R DLBCL
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education (CE) for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this virtually live activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the virtually live activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hour.
PHARMACISTS AND PHARMACY TECHNICIANS (ACPE) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of up to 1.0 knowledge-based CPE contact hours.
NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 45 days of your participation in the activity to meet the deadline for submission to CPE Monitor. Credits are generally reported during the first week of each month for those who claimed during the month prior.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture the faculty may mention the use of medications for both US Food and Drug Administration (FDA)-approved and non-FDA-approved indications.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science-based.
This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at info@medlearninggroup.com
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
